These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1379 related articles for article (PubMed ID: 23961726)

  • 1. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study.
    Bakouni H; Haquet L; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
    J Addict Med; 2024 Mar-Apr 01; 18(2):167-173. PubMed ID: 38258865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
    Soyka M; Hillemacher T
    Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
    Hser YI; Evans E; Huang D; Weiss R; Saxon A; Carroll KM; Woody G; Liu D; Wakim P; Matthews AG; Hatch-Maillette M; Jelstrom E; Wiest K; McLaughlin P; Ling W
    Addiction; 2016 Apr; 111(4):695-705. PubMed ID: 26599131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.
    Bakouni H; McAnulty C; Tatar O; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
    Am J Addict; 2023 Sep; 32(5):469-478. PubMed ID: 37308805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
    Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
    Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
    Bakouni H; Sharafi H; Drouin S; Fortin R; Marsan S; Brissette S; Socias ME; Le Foll B; Lim R; Jutras-Aswad D
    Can J Psychiatry; 2024 Apr; 69(4):252-263. PubMed ID: 37899716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
    Evans EA; Zhu Y; Yoo C; Huang D; Hser YI
    Addiction; 2019 Aug; 114(8):1396-1404. PubMed ID: 30916463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated measures analysis of opioid use disorder treatment on clinical opiate withdrawal scale in a randomized clinical trial: sex differences.
    Wang K; Shafique S; Xiao D; Walter SM; Liu Y; Piamjariyakul U; Xie C
    J Addict Dis; 2024; 42(1):33-44. PubMed ID: 36655851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial.
    McAnulty C; Bastien G; Eugenia Socias M; Bruneau J; Foll BL; Lim R; Brissette S; Ledjiar O; Marsan S; Talbot A; Jutras-Aswad D;
    Drug Alcohol Depend; 2022 Oct; 239():109604. PubMed ID: 36037586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
    Sadek J; Saunders J
    BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).
    Potter JS; Marino EN; Hillhouse MP; Nielsen S; Wiest K; Canamar CP; Martin JA; Ang A; Baker R; Saxon AJ; Ling W
    J Stud Alcohol Drugs; 2013 Jul; 74(4):605-13. PubMed ID: 23739025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder.
    Rudolph KE; Williams NT; Goodwin ATS; Shulman M; Fishman M; Díaz I; Luo S; Rotrosen J; Nunes EV
    Drug Alcohol Depend; 2022 Oct; 239():109609. PubMed ID: 36075154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.
    Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM
    Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.
    Lucas GM; Young A; Donnell D; Richardson P; Aramrattana A; Shao Y; Ruan Y; Liu W; Fu L; Ma J; Celentano DD; Metzger D; Jackson JB; Burns D;
    Drug Alcohol Depend; 2014 Sep; 142():139-45. PubMed ID: 24999060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
    Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
    JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
    Altice FL; Bruce RD; Lucas GM; Lum PJ; Korthuis PT; Flanigan TP; Cunningham CO; Sullivan LE; Vergara-Rodriguez P; Fiellin DA; Cajina A; Botsko M; Nandi V; Gourevitch MN; Finkelstein R;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S22-32. PubMed ID: 21317590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
    Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
    Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
    Moore K; Magee M; Sevinsky H; Chang M; Lubin S; Myers E; Ackerman P; Llamoso C
    Br J Clin Pharmacol; 2019 Aug; 85(8):1771-1780. PubMed ID: 30980734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.